-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5

Benzinga·03/05/2026 13:49:07
Listen to the news
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.